Repositive expands global cancer model network with CRO from Finland Kumar Jeetendra | November 10, 2020 CAMBRIDGE, UK – (November 10, 2020) – Life Science Newswire – Repositive, the world’s largest directory of preclinical cancer models, has expanded its global network of contract research organisation (CRO) partners with the addition of Pharmatest, a CRO providing clinically predictive preclinical efficacy services for oncology and skeletal diseases. Pharmatest brings to the partnership more …
BioNTech Expects immunisation effect of COVID-19 vaccine will last at least a year Kumar Jeetendra | November 9, 2020 BioNTech’s co-founder and chief executive said that he was hopeful that the protective effect of its experimental COVID-19 vaccine, co-developed with Pfizer, would endure for at least a year. Both companies earlier on Monday became the primary drugmakers to launch successful trial statistics, stating their vaccine was demonstrated to be 90 percent successful, a major …
AstraZeneca expects COVID-19 immunization information this year Kumar Jeetendra | November 5, 2020 AstraZeneca, the British drugmaker working on one of the world’s leading COVID-19 vaccine candidates, conquer third-quarter sales estimates on Thursday and reiterated it expects data from late-stage trials of the vaccine later this year. The business has taken on the development of Oxford University’s potential COVID-19 vaccine, scoring billions in funding and signing multiple prices …
Lincoln Pharmaceuticals Ltd reports 16.70% rise in the Standalone Net Profit at Rs. 35.19 crore in H1 FY21 Kumar Jeetendra | November 3, 2020 November 03, 2020: Lincoln Pharmaceuticals Limited, one of India’s leading healthcare companies has reported net profit of Rs. 35.19 crore for the H1 FY21 ended September 2020 as against net profit of Rs. 30.15 crore in the corresponding period last year, growth of 16.70%. Net revenue for the half year ended September 2020 reported at …
Zydus Cadila finishes stage 2 preliminary, to submit information in November Kumar Jeetendra | November 3, 2020 Cadila Healthcare (Zydus Cadila) said it has completed enrolment and dosing of 1,000 volunteers in phase-2 clinical trials of its possible Covid-19 vaccine, ZyCoV-D, and plans to submit the data to the Drug Controller General of India (DCGI) this past month. “At present the immunogenicity evaluation is going on,” said Sharvil Patel, Managing Director of …
Johnson and Johnson intends to test its COVID-19 antibody in ages 12-18 soon Kumar Jeetendra | October 31, 2020 Based on safety and other things, the company intends to check in even younger children afterwards, said Sadoff, a vaccine research scientist in J&J’s Janssen unit, without giving a timeline. J&J said in a statement it is currently in discussions with partners and regulators concerning the addition of the pediatric population in its trials. The …
Cipla launches ‘ELIFast’ (IgG ELISA test) for COVID-19 antibody detection Kumar Jeetendra | October 28, 2020 Mumbai, India; October 28, 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as “Cipla,” today announced the commercialisation of antibody detection kits for COVID-19 in India. In partnership with KARWA Ltd. under the technology transfer from the Indian Council of Medical Research (ICMR). As part of this collaborative effort, Cipla will be responsible …
Pfizer not yet prepared to deliver COVID-19 vaccine data Kumar Jeetendra | October 27, 2020 Drugmaker Pfizer Inc said on October 27 that it wasn’t yet ready to release data in the late-stage trial of the COVID-19 vaccine candidate it is growing with Germany’s BioNTech SE. Pfizer’s CEO Albert Bourla has said the company could release data on whether or not the vaccine works as early as this month, but …
Zydus Cadila gets USFDA nod for generic medication Kumar Jeetendra | October 23, 2020 New Delhi, Oct 23 (PTI) Drug firm Zydus Cadila on Friday said it has received approval from the US health regulator to market Albuterol tablets, used to treat shortness of breath caused by breathing problems like asthma. The company has received final approval from the US Food and Drug Administration (USFDA) to market its product, …
USFDA supports remdesivir, first medication to treat Covid-19 patients Kumar Jeetendra | October 23, 2020 Washington: The United States Food and Drug Administration (FDA) has approved Remdesivir for the treatment of coronavirus, Al Jazeera reported citing a statement issued by Gilead Sciences, Inc.. Based on the press release by the company, previously authorised by the FDA for just emergency use to deal with Covid-19 patients, Veklury or Remdesivir is now …
XL-protein and Antlia Bioscience Announce Collaboration to Develop Long-acting Peptide Therapy of Chronic Heart Failure using PASylation® Technology Kumar Jeetendra | October 22, 2020 SAN DIEGO, U.S.A., and FREISING, Germany, October 15, 2020 – Life Science Newswire – Antlia Bioscience, Inc., a privately owned biopharmaceutical company located in San Diego, California, and XL-protein GmbH, a privately owned biopharmaceutical company located in Germany, are pleased to announce a strategic slliance using XL-protein’s proprietary PASylation® technology for plasma half-life extension to …
SB3000 partners with Evaxion biotech to provide rapid scale up for commercial production of corona virus vaccines Kumar Jeetendra | October 21, 2020 Evaxion Biotech A/S has received funding from the Danish Innovation Fund to further develop their AI platform RAVEN to rapidly respond against future corona virus pandemics – from initial discovery to first in human trials in as little as 13 weeks. During those 13 weeks SB3000 intends to develop and validate a tailored μLOT® continuous …
